Clinical Research Directory
Browse clinical research sites, groups, and studies.
Real World Evidence Clinical Utility Study of KidneyIntelX
Sponsor: Renalytix AI, Inc.
Summary
The purpose of this study is to assess the impact of the KidneyIntelX assay utilized as part of the current standard of care on the management of patients seen in the primary care physician's office at Mount Sinai.
Official title: Real World Evidence Clinical Utility Study of KidneyIntelX in Patients With Type 2 Diabetes and Chronic Kidney Disease
Key Details
Gender
All
Age Range
23 Years - Any
Study Type
OBSERVATIONAL
Enrollment
10000
Start Date
2021-03-02
Completion Date
2026-12-01
Last Updated
2024-04-12
Healthy Volunteers
No
Interventions
KidneyIntelX
KidneyIntelX is an in-vitro diagnostic that enables accurate risk prediction of progressive decline in kidney function in patients with type 2 diabetes and existing CKD at stages 1-3 (eGFR of 30 to 59 ml/min/1.73m2, or eGFR ≥ 60 ml/min/1.73m2 and uACR ≥ 30 mg/g).
Locations (1)
Mount Sinai Health System
New York, New York, United States